Emerging Therapies Targeting Lipoprotein(a): A Clinical Trial Landscape Review of Investigational Lp(a)-Lowering Therapies.
Level 5 - mechanism / opinion, no new human data
Qualitative landscape review and narrative synthesis of trial registry records without meta-analysis.
PubMed 42452692 · doi:10.3390/jcm15135233
What was done
The authors conducted a qualitative landscape review of clinical trials registered on ClinicalTrials.gov as of November 5, 2025. They identified Phase I–III interventional trials evaluating therapies specifically targeting lipoprotein(a) [Lp(a)]. Extracted data included trial characteristics, drug classes, endpoint methodologies, and published efficacy data, synthesized narratively.
What was found
Twenty clinical trials met eligibility criteria across three drug classes: antisense oligonucleotides (pelacarsen), small interfering RNA (siRNA, the largest class), and small-molecule inhibitors (muvalaplin). Five studies were designed as cardiovascular outcomes trials. The primary efficacy endpoint across trials was percent change from baseline in circulating Lp(a). The abstract reports substantial Lp(a) reductions across all platforms but provides no specific numerical values or effect sizes.
Why it matters
This review outlines the rapidly expanding pipeline of targeted Lp(a) agents, underscoring that while potent biomarker lowering is feasible across multiple therapeutic modalities, evidence of clinical cardiovascular risk reduction awaits results from ongoing outcome trials.
Limits
The abstract provides no numerical effect sizes or statistical metrics. The search was confined to ClinicalTrials.gov and analyzed qualitatively without meta-analysis or head-to-head comparisons, and cardiovascular outcome efficacy remains unproven.
Cited by
- supports Evidence has not been substantial enough to prove that lowering lipoprotein(a) prevents heart attacks.